Related references
Note: Only part of the references are listed.HIV-1 Resistance Dynamics in Patients With Virologic Failure to Dolutegravir Maintenance Monotherapy
Ingeborg E. A. Wijting et al.
JOURNAL OF INFECTIOUS DISEASES (2018)
The S230R Integrase Substitution Associated With Virus Load Rebound During Dolutegravir Monotherapy Confers Low-Level Resistance to Integrase Strand-Transfer Inhibitors
Hanh T. Pham et al.
JOURNAL OF INFECTIOUS DISEASES (2018)
TLR7 agonists induce transient viremia and reduce the viral reservoir in SIV-infected rhesus macaques on antiretroviral therapy
So-Yon Lim et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
ACTG A5353: A Pilot Study of Dolutegravir Plus Lamivudine for Initial Treatment of Human Immunodeficiency Virus-1 (HIV-1)-infected Participants With HIV-1 RNA < 500 000 Copies/mL
Babafemi O. Taiwo et al.
CLINICAL INFECTIOUS DISEASES (2018)
Dolutegravir monotherapy as treatment de-escalation in HIV-infected adults with virological control: DoluMono cohort results
Celia Oldenbuettel et al.
ANTIVIRAL THERAPY (2017)
Dolutegravir monotherapy: when should clinical practice be clinical research?
Joel Gallant et al.
ANTIVIRAL THERAPY (2017)
Monotherapy with either dolutegravir or raltegravir fails to durably suppress HIV viraemia in humanized mice
Alonso Heredia et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
Human Immunodeficiency Virus Type 1 Drug Resistance Mutations Update
Robert W. Shafer
JOURNAL OF INFECTIOUS DISEASES (2017)
Key Factors Influencing the Emergence of Human Immunodeficiency Virus Drug Resistance in Low- and Middle-Income Countries
Carole L. Wallis et al.
JOURNAL OF INFECTIOUS DISEASES (2017)
Tackling HIV and AIDS: contributions by non-human primate models
Koen K. A. Van Rompay
LAB ANIMAL (2017)
Dolutegravir as maintenance monotherapy for HIV (DOMONO): a phase 2, randomised non-inferiority trial
Ingeborg Wijting et al.
LANCET HIV (2017)
Collaborative update of a rule-based expert system for HIV-1 genotypic resistance test interpretation
Roger Paredes et al.
PLOS ONE (2017)
Antiviral Activity of Bictegravir and Cabotegravir against Integrase Inhibitor-Resistant SIVmac239 and HIV-1
Said A. Hassounah et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Dolutegravir-based monotherapy or dual therapy maintains a high proportion of viral suppression even in highly experienced HIV-1-infected patients
Camelia Gubavu et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2016)
Short Communication: Comparative Evaluation of Coformulated Injectable Combination Antiretroviral Therapy Regimens in Simian Immunodeficiency Virus-Infected Rhesus Macaques
Gregory Q. Del Prete et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2016)
Dolutegravir Monotherapy in HIV-Infected Naive Patients With <100,000 Copies/mL HIV RNA Load
Massimiliano Lanzafame et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2016)
Dolutegravir monotherapy in HIV-infected patients with sustained viral suppression
Jhon Rojas et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2016)
Dolutegravir as monotherapy in HIV-1-infected individuals with suppressed HIV viraemia
C. Katlama et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2016)
Dolutegravir as maintenance monotherapy: first experiences in HIV-1 patients
Casper Rokx et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2016)
Development of a G118R mutation in HIV-1 integrase following a switch to dolutegravir monotherapy leading to cross-resistance to integrase inhibitors
Bluma G. Brenner et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2016)
Envelope residue 375 substitutions in simian-human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques
Hui Li et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Sustained virologic control in SIV+ macaques after antiretroviral and α4β7 antibody therapy (Publication with Expression of Concern. See vol. 365, pg. 991, 2019)
Siddappa N. Byrareddy et al.
SCIENCE (2016)
Population pharmacokinetics of dolutegravir in HIV-infected treatment-naive patients
Jianping Zhang et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Characterization of the Drug Resistance Profiles of Integrase Strand Transfer Inhibitors in Simian Immunodeficiency Virus SIVmac239
Said A. Hassounah et al.
JOURNAL OF VIROLOGY (2015)
A Vaccine against CCR5 Protects a Subset of Macaques upon Intravaginal Challenge with Simian Immunodeficiency Virus SIVmac251
Koen K. A. Van Rompay et al.
JOURNAL OF VIROLOGY (2014)
Effect of HIV-1 Integrase Resistance Mutations When Introduced into SIVmac239 on Susceptibility to Integrase Strand Transfer Inhibitors
Said A. Hassounah et al.
JOURNAL OF VIROLOGY (2014)
Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys
James B. Whitney et al.
NATURE (2014)
The R263K mutation in HIV integrase that is selected by dolutegravir may actually prevent clinically relevant resistance to this compound
Mark Wainberg et al.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY (2014)
Impact of Primary Elvitegravir Resistance-Associated Mutations in HIV-1 Integrase on Drug Susceptibility and Viral Replication Fitness
Michael E. Abram et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
What if HIV were unable to develop resistance against a new therapeutic agent?
Mark A. Wainberg et al.
BMC MEDICINE (2013)
Haplessly Hoping: Macaque Major Histocompatibility Complex Made Easy
Roger W. Wiseman et al.
ILAR JOURNAL (2013)
Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study
Pedro Cahn et al.
LANCET (2013)
Determinants of HIV drug resistance and public health implications in low- and middle-income countries
Silvia Bertagnolio et al.
ANTIVIRAL THERAPY (2012)
Characterization of the R263K Mutation in HIV-1 Integrase That Confers Low-Level Resistance to the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir
Peter K. Quashie et al.
JOURNAL OF VIROLOGY (2012)
Prolonged tenofovir treatment of macaques infected with K65R reverse transcriptase mutants of SIV results in the development of antiviral immune responses that control virus replication after drug withdrawal
Koen K. A. Van Rompay et al.
RETROVIROLOGY (2012)
SIV Replication in the Infected Rhesus Macaque Is Limited by the Size of the Preexisting TH17 Cell Compartment
Dennis J. Hartigan-O'Connor et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Mamu-B*08-positive macaques control simian immunodeficiency virus replication
John T. Loffredo et al.
JOURNAL OF VIROLOGY (2007)
Structured treatment interruptions with tenofovir monotherapy for simian immunodeficiency virus-infected newborn macaques
Koen K. A. Van Rompay et al.
JOURNAL OF VIROLOGY (2006)
The high-frequency major histocompatibility complex class I allele Mamu-B*17 is associated with control of simian immunodeficiency virus SIVmac239 replication
Levi J. Yant et al.
JOURNAL OF VIROLOGY (2006)
Attenuated poxvirus-based simian immunodeficiency virus (SIV) vaccines given in infancy partially protect infant and juvenile macaques against repeated oral challenge with virulent SIV
KKA Van Rompay et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2005)
The clinical benefits of tenofovir for simian immunodeficiency virus-infected macaques are larger than predicted by its effects on standard viral and immunologic parameters
KKA Van Rompay et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2004)
CD8+-cell-mediated suppression of virulent simian immunodeficiency virus during tenofovir treatment
KKA Van Rompay et al.
JOURNAL OF VIROLOGY (2004)
Expression of the major histocompatibility complex class I molecule Mamu-A*01 is associated with control of simian immunodeficiency virus SIVmac239 replication
BR Mothé et al.
JOURNAL OF VIROLOGY (2003)
Virulence and reduced fitness of simian immunodeficiency virus with the M184V mutation in reverse transcriptase
KKA Van Rompay et al.
JOURNAL OF VIROLOGY (2002)
Share Paper
